Alex Goldberg

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) and Clovis Oncology, Inc. (NASDAQ:CLVS) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 12/04/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) and Clovis Oncology, Inc. (NASDAQ:CLVS).

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biotechnology company that focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem Cells is currently up (+12.49%) on 1,573,502 shares traded after OncoMed price target raised to $46 from $27 at Jefferies. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is currently up (+165.12%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

Clovis Oncology, Inc. (NASDAQ:CLVS) a biopharmaceutical company that focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally is currently down (-3.48%) on 940,727 shares traded after Clovis Oncology announced public offering of 2 mln shares of common stock by selling stockholders at $57.50 per share. Clovis Oncology, Inc. (NASDAQ:CLVS) is currently down (-34.23%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Clovis Oncology, Inc. (NASDAQ:CLVS)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com